List of YUEMIA MedChat Customers
Shanghai, 201500,
China
Since 2010, our global team of researchers has been studying YUEMIA MedChat customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased YUEMIA MedChat for Chatbots and Conversational AI from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using YUEMIA MedChat for Chatbots and Conversational AI include: Sanofi China, a China based Life Sciences organisation with 7000 employees and revenues of $2.00 billion, Medtronic China, a China based Healthcare organisation with 989 employees and revenues of $1.50 billion, Shanghai Abbott Pharmaceutical Co., a China based Life Sciences organisation with 80 employees and revenues of $8.0 million and many others.
Contact us if you need a completed and verified list of companies using YUEMIA MedChat, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The YUEMIA MedChat customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight | Insight Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Medtronic China | Healthcare | 989 | $1.5B | China | YUEMIA | YUEMIA MedChat | Chatbots and Conversational AI | 2018 | n/a | In 2018, Medtronic China deployed YUEMIA MedChat in a Chatbots and Conversational AI implementation to support medical device marketing, clinician engagement, and patient education workflows in China. The deployment targeted online academic activities and conversational engagement channels to extend academic outreach and reduce reliance on in person medical representative visits. YUEMIA MedChat was configured to deliver conversational workflows, knowledge driven responses, and structured patient education sequences, leveraging MedChat module capabilities typical of the Chatbots and Conversational AI category. The configuration focused on content authoring for academic materials, scripted clinician engagement flows, and automation of routine information requests from clinicians and patients. Operational scope covered medical affairs, marketing, and patient education functions within Medtronic China, supporting both clinician facing and patient facing use cases across applicable device portfolios. The implementation emphasized virtual academic sessions and asynchronous Q and A as primary engagement channels, shifting certain outreach activities away from in person events toward scalable conversational interfaces. Governance and rollout concentrated on content control and clinical review workflows to ensure compliant educational messaging when using YUEMIA MedChat, aligning content authoring with medical review cycles. The deployment helped streamline online academic activities and reduced reliance on in person medical representative visits, consistent with the vendor launch history and declared client roster. | |
|
|
Sanofi China | Life Sciences | 7000 | $2.0B | China | YUEMIA | YUEMIA MedChat | Chatbots and Conversational AI | 2017 | n/a | In 2017 Sanofi China deployed YUEMIA MedChat, a Chatbots and Conversational AI application, to support digital medical and marketing communications and doctor community engagement across the China region. The implementation positioned YUEMIA MedChat as a conversational engagement layer for medical affairs and marketing teams, centralizing online academic promotion and scalable outreach to physician communities. The deployment used the YUEMIA MedChat module to provision conversational workflows, automated messaging and campaign orchestration consistent with Chatbots and Conversational AI patterns. Configuration focused on scripted clinical Q&A flows, scheduled broadcast campaigns, and content management for academic promotion, enabling moderated community interactions and automated follow up for event and education outreach. Operational coverage was scoped to China with medical affairs and marketing as primary business functions impacted, and rollout staged to support scalable online academic promotion and broader campaign reach. Governance emphasized content approval workflows and moderator operations to align communications with medical and regulatory requirements, and outcomes reported include improved campaign reach and the ability to scale online academic promotion. | |
 |
Shanghai Abbott Pharmaceutical Co. | Life Sciences | 80 | $8M | China | YUEMIA | YUEMIA MedChat | Chatbots and Conversational AI | 2016 | n/a | In 2016 Shanghai Abbott Pharmaceutical Co. deployed YUEMIA MedChat to support medical marketing, physician engagement and patient-education workflows across China. YUEMIA MedChat is a Chatbots and Conversational AI application used to expand digital outreach and help reduce field-marketing costs by automating routine engagement and educational interactions. The implementation centered on the MedChat conversational module, configured to deliver multi-role conversational flows for physicians and patients and to sequence educational content for patient-education workflows. Functional capabilities implemented included automated question and answer handling, scheduled messaging for campaign orchestration, and content management for clinical and promotional materials, aligned with medical marketing use cases. Configuration emphasized role-based content delivery and conversational logic to route inquiries to appropriate follow up channels when needed. Operational coverage spanned national field-marketing teams and digital engagement channels across China, with primary business functions impacted including medical affairs, marketing, and patient support. Governance and process alignment focused on content oversight between medical affairs and marketing to ensure consistent clinical messaging and regulatory compliance. Vendor materials cite outcomes of expanded digital outreach and reduced field-marketing costs as justification for the deployment of YUEMIA MedChat. |
Buyer Intent: Companies Evaluating YUEMIA MedChat
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated | ||
|---|---|---|---|---|---|---|---|---|
| No data found | ||||||||